Why Evaxion A/S’s (EVAX) Stock Is Down 6.03%
As of Wednesday, December 10, Evaxion A/S’s EVAX share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Commentary & Analysis
Why Evaxion A/S’s (EVAX) Stock Is Up 8.28%
As of Tuesday, December 09, Evaxion A/S’s EVAX share price has surged by 8.28%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Evaxion A/S’s (EVAX) Stock Is Down 32.29%
As of Friday, October 17, Evaxion A/S’s EVAX share price has dipped by 32.29%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Evaxion A/S’s (EVAX) Stock Is Down 5.35%
As of Thursday, October 16, Evaxion A/S’s EVAX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Evaxion Biotech A/S - ADR (EVAX) Stock a Good Investment?
Learn more about Evaxion Biotech A/S - ADR's (EVAX) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | EVAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24.8 | $227.3 | 12% |
|
| Shares Out (Mil) | 7.4 | 53.4 | 18% |
|
| Institutional Ownership | 76.1% | 92.9% | 46% |
|
| Float (Mil) | 5.7 | 41.4 | 13% |
|
| Beta | 0.27 | 0.95 | 16% |
|
| Avg Daily Volume (000s) | 80 | 468 | 34% |
|
| Price Change (52-week) |
(48.5%) | 47.4% | 20% |
|
| Growth | EVAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 12.5% | (10.1%) | 59% |
|
| EPS (5yr) | 52.3% | 15.8% | 94 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 17.3% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 2 | 2 | |
| Current EPS | ($0.010) | ($0.040) | ($0.015) | |
| Month Ago EPS | ($0.010) | ($0.040) | ($0.015) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.010) | ($0.040) | $0.040 | |
| Year/Year Chg | (98.0%) | (96.7%) | (100.0%) | |
| Financials | EVAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($9) | ($44) | 30% |
|
| EPS (TTM) | ($1.089) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($34) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $20 | $174 | 11% |
|
| Valuation | EVAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.61 | 2.14 | 63% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EVAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.5% | 96% |
|
| Net Margin | (115.5%) | (69.8%) | 7% |
|
| ROA | (50.0%) | (47.1%) | 12% |
|
| ROE | (160.5%) | (52.0%) | 5% |
|
| Liabilities to Assets | 50.8% | 29.7% | 43% |
|
| F-Score | 4 | 2 | 33% |
|
Evaxion A/S did not pass any screens on 11/4/2026.
